BioNexus Gene Lab Corp. (BGLC) vs DEFSEC Technologies Inc. (DFSC)
A side-by-side comparison of BioNexus Gene Lab Corp. and DEFSEC Technologies Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BGLC
BioNexus Gene Lab Corp.
$1.28IndustrialsDelayed quote: Oct 5, 2026, 4:00 PM EDT
DFSC
DEFSEC Technologies Inc.
$1.01IndustrialsDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — BGLC vs DFSC
growth of $100 · dividends reinvested · last 6yBGLC -99.5% (-58.9%/yr)DFSC -100.0% (-79.9%/yr)BGLC compounded faster over this window
Log scale — wide-divergence pair
BGLC DFSC
BGLC vs DFSC: by the numbers
- •BGLC is the larger company ($3M vs $3M market cap).
- •Both run net losses; BGLC's is the smaller (-82.36% vs -121.26% net margin).
Metrics side by side
Valuation
| Metric | BGLC | DFSC |
|---|---|---|
| P/S ratio | 0.99 | 0.50 |
| P/B ratio | 0.40 | 0.75 |
Profitability
| Metric | BGLC | DFSC |
|---|---|---|
| Gross margin | 11.64% | 32.11% |
| Operating margin | -42.54% | -183.72% |
| Net margin | -82.36% | -121.26% |
| ROE | -33.11% | -181.23% |
| ROIC | -32.71% | -127.61% |
Growth (annualized)
| Metric | BGLC | DFSC |
|---|---|---|
| Revenue CAGR (5Y) | -31.68% | N/A |
| Total return CAGR (5Y) | -61.00% | -86.24% |
Frequently asked
- How have BGLC and DFSC total returns compared?
- Over the past 5 years, BGLC delivered -61.00% and DFSC delivered -86.24% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.